Rep. Jefferson Shreve Purchases Shares of Charles River Laboratories International, Inc. (NYSE:CRL)

Representative Jefferson Shreve (R-Indiana) recently bought shares of Charles River Laboratories International, Inc. (NYSE:CRL). In a filing disclosed on June 22nd, the Representative disclosed that they had bought between $15,001 and $50,000 in Charles River Laboratories International stock on May 8th. The trade occurred in the Representative’s “CRT – STANDARD UNIT TRUST” account.

Representative Jefferson Shreve also recently made the following trade(s):

• Sold $15,001 – $50,000 in shares of Hubbell (NYSE:HUBB) on 5/12/2025.
• Sold $50,001 – $100,000 in shares of Trane Technologies (NYSE:TT) on 5/12/2025.
• Sold $15,001 – $50,000 in shares of RTX (NYSE:RTX) on 5/12/2025.
• Sold $50,001 – $100,000 in shares of NiSource (NYSE:NI) on 5/12/2025.
• Sold $50,001 – $100,000 in shares of Johnson & Johnson (NYSE:JNJ) on 5/12/2025.
• Sold $15,001 – $50,000 in shares of AppLovin (NASDAQ:APP) on 5/12/2025.
• Sold $15,001 – $50,000 in shares of Fiserv (NYSE:FI) on 5/12/2025.
• Sold $15,001 – $50,000 in shares of CNO Financial Group (NYSE:CNO) on 5/12/2025.
• Sold $50,001 – $100,000 in shares of Cboe Global Markets (NASDAQ:CBOE) on 5/12/2025.
• Sold $15,001 – $50,000 in shares of Lam Research (NASDAQ:LRCX) on 5/12/2025.

Charles River Laboratories International Stock Down 1.6%

Shares of NYSE:CRL opened at $166.89 on Friday. The company has a current ratio of 1.43, a quick ratio of 1.16 and a debt-to-equity ratio of 0.78. The company has a fifty day simple moving average of $153.56 and a 200 day simple moving average of $149.56. The firm has a market cap of $8.20 billion, a PE ratio of -256.75, a price-to-earnings-growth ratio of 5.65 and a beta of 1.48. Charles River Laboratories International, Inc. has a 12-month low of $91.86 and a 12-month high of $236.88.

Charles River Laboratories International (NYSE:CRL) last issued its quarterly earnings results on Wednesday, May 7th. The medical research company reported $2.34 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $2.06 by $0.28. The business had revenue of $984.17 million during the quarter, compared to analyst estimates of $942.34 million. Charles River Laboratories International had a negative net margin of 0.66% and a positive return on equity of 15.19%. The business’s revenue was down 2.7% compared to the same quarter last year. During the same quarter in the previous year, the firm earned $2.27 earnings per share. On average, equities research analysts anticipate that Charles River Laboratories International, Inc. will post 9.36 EPS for the current fiscal year.

Analysts Set New Price Targets

A number of analysts recently issued reports on the stock. Citigroup upgraded shares of Charles River Laboratories International from a “neutral” rating to a “buy” rating and lifted their price target for the stock from $150.00 to $200.00 in a research note on Wednesday, July 9th. Cowen upgraded shares of Charles River Laboratories International from a “hold” rating to a “buy” rating in a research note on Wednesday, May 14th. Evercore ISI lifted their price target on shares of Charles River Laboratories International from $170.00 to $180.00 and gave the stock an “outperform” rating in a research note on Wednesday, July 9th. TD Cowen upgraded shares of Charles River Laboratories International from a “hold” rating to a “buy” rating and set a $179.00 target price for the company in a research note on Wednesday, May 14th. Finally, Mizuho lowered their target price on shares of Charles River Laboratories International from $175.00 to $155.00 and set a “neutral” rating for the company in a research note on Wednesday, April 9th. One analyst has rated the stock with a sell rating, eleven have assigned a hold rating and five have assigned a buy rating to the company. Based on data from MarketBeat, the company presently has an average rating of “Hold” and an average price target of $174.54.

Hedge Funds Weigh In On Charles River Laboratories International

Several hedge funds and other institutional investors have recently modified their holdings of the company. Vanguard Group Inc. boosted its holdings in shares of Charles River Laboratories International by 1.0% during the fourth quarter. Vanguard Group Inc. now owns 6,158,926 shares of the medical research company’s stock valued at $1,136,938,000 after acquiring an additional 60,497 shares during the period. Wellington Management Group LLP boosted its holdings in shares of Charles River Laboratories International by 5.1% during the first quarter. Wellington Management Group LLP now owns 4,285,012 shares of the medical research company’s stock valued at $644,980,000 after acquiring an additional 208,586 shares during the period. Allspring Global Investments Holdings LLC boosted its holdings in shares of Charles River Laboratories International by 29.1% during the second quarter. Allspring Global Investments Holdings LLC now owns 2,291,126 shares of the medical research company’s stock valued at $353,750,000 after acquiring an additional 516,521 shares during the period. Kayne Anderson Rudnick Investment Management LLC boosted its holdings in shares of Charles River Laboratories International by 8.0% during the first quarter. Kayne Anderson Rudnick Investment Management LLC now owns 1,950,273 shares of the medical research company’s stock valued at $293,555,000 after acquiring an additional 144,732 shares during the period. Finally, Geode Capital Management LLC boosted its holdings in shares of Charles River Laboratories International by 1.2% during the fourth quarter. Geode Capital Management LLC now owns 1,233,211 shares of the medical research company’s stock valued at $227,042,000 after acquiring an additional 14,787 shares during the period. Institutional investors and hedge funds own 98.91% of the company’s stock.

Insider Activity

In other news, EVP Joseph W. Laplume sold 500 shares of the business’s stock in a transaction on Tuesday, May 13th. The shares were sold at an average price of $145.41, for a total transaction of $72,705.00. Following the completion of the transaction, the executive vice president owned 19,513 shares of the company’s stock, valued at approximately $2,837,385.33. The trade was a 2.50% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which can be accessed through the SEC website. Company insiders own 1.30% of the company’s stock.

About Representative Shreve

Jefferson Shreve (Republican Party) is a member of the U.S. House, representing Indiana’s 6th Congressional District. He assumed office on January 3, 2025. His current term ends on January 3, 2027.

Shreve (Republican Party) is running for re-election to the U.S. House to represent Indiana’s 6th Congressional District. He declared candidacy for the 2026 election.

Email [email protected] to notify us of updates to this biography.
Jefferson Shreve earned a bachelor’s degree from Indiana University in 1989, a graduate degree from the University of London in 1998, and a graduate degree from Purdue University in 2003. Shreve’s career experience includes working as a real estate executive.

Shreve was elected 7th District Vice Chairman of the Indiana Republican State Committee on January 17, 2018, and was re-elected on March 6, 2021. In 2020, he was selected as a district-level delegate to the 2020 Republican National Convention.

About Charles River Laboratories International

Charles River Laboratories International, Inc provides drug discovery, non-clinical development, and safety testing services in the United States, Europe, Canada, the Asia Pacific, and internationally. It operates through three segments: Research Models and Services (RMS), Discovery and Safety Assessment (DSA), and Manufacturing Solutions (Manufacturing).